Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2914 - Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Eiji Oki

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

E. Oki1, H. Samura2, H. Okumura3, T. Ohchi4, H. Orita5, K. Kobayashi6, T. Kinjo7, S. Mori8, T. Touyama9, K. Ohgaki10, H. Kawanaka11, A. Makiyama12, N. Ureshino13, M. Kotaka14, T. Shimose15, H. Saeki16, T. Nishimaki17, H. Baba18, Y. Maehara19

Author affiliations

  • 1 Surgery And Science, Kyushu University Hospital, 812-8582 - FUKUOKA/JP
  • 2 Surgery, Urazoe General Hospital, Okinawa/JP
  • 3 Surgery, Kagoshima kouseiren hospital, Kagoshima/JP
  • 4 Surgery, Social Insurance Tagawa Hospital, Kurume/JP
  • 5 Department Of Surgery, NAKATSU MUNICIPAL HOSPITAL, Nakatsu/JP
  • 6 Department Of Surgery, Nagaski University Hospital, 852-8501 - Nagasaki/JP
  • 7 Surgery, Ryukyu University, Okinawa/JP
  • 8 Department Of Digestive Surgery, Breast And Thyroid Surgery, Kagoshima University, Kaghosima/JP
  • 9 Surgery, Nakagami Hospital, 904-2143 - Okinawa/JP
  • 10 Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, FUKUOKA/JP
  • 11 Surgery, National Beppu Medical Center, Beppu/JP
  • 12 Medical Oncology, Japan Community Healthcare Organization Kyushu Hospital, FUKUOKA/JP
  • 13 Medical Oncology, Saga-Ken Medical Center Koseikan, Saga/JP
  • 14 Surgery, Sano Hospital-Gastrointestinal Cancer Centre, 655-0031 - Kobe/JP
  • 15 Biostatistics, Clinical research Support Center Kyushu, Fukuoka/JP
  • 16 Department Of Surgery And Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka/JP
  • 17 Unit Of Organ0oriented Medicine Division Of Digestive And General Surgery First Depertment Of Surgery, Ryukyu University, Okinawa/JP
  • 18 Gastrointestinal Surgery, Kumamoto University, 860-8556 - Kumamoto/JP
  • 19 -, Kyushu Central Hospital of the Mutural Aid Association of Public School Teachers, Fukuoka/JP
More

Resources

Abstract 2914

Background

Combination therapy with oral fluoropyrimidine and irinotecan with cetuximab has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC). This study was designed to assess the tolerability of different doses of tri-weekly intravenous infusion of irinotecan in combination with S-1 (IRIS) and weekly cetuximab (phase I) and explore the efficacy and safety of the IRIS in combination with cetuximab in patients with mCRC (phase II).

Methods

Main eligibility was RAS (exon 2) wild-type mCRC and without any prior chemotherapy except for adjuvant therapy. S-1 was given orally at a dose of 40 mg/m2 (40-60mg) twice for 2 weeks, followed by a 1-week rest. Irinotecan (150mg/m2) was given on days 1. Cetuximab was administered on days 1 (400 mg/ m2), 8 (250 mg/ m2) and 15 (250 mg/ m2), followed by every week (250 mg/ m2) thereafter. A standard 3 + 3 phase I dose de-escalation design was utilized to decide maximum tolerant dose (MTD) and recommend dose (RD) of irinotecan. Primary endpoint of Phase II part was overall response rate (ORR). We set the expected and threshold RRs at 60% and 40%, respectively. ORR was assessed by central office according to RECIST version 1.1 criteria.

Results

Between December 2014 and September 2017, 58 patients were enrolled. Seven patients were excluded owing to ineligibility. No dose limiting toxicity was observed in phase I part and RD irinotecan was decided at 150mg/m2. In phase II part, the treatment response with confirmation was complete response (CR) in 1, and partial response (PR) in 28, stable disease (SD) in 15, progressive disease (PD) in 6, not evaluated (NE) in 1, final response rate was 56.9% (90 %; CI 44.4 – 68.7 %, p = 0.011). The safety profile revealed the common Grade 3/4 adverse events to be neutropenia (31.4%), appetite loss (27.5%), hypokalemia (11.8%) and diarrhea (11.8%). Grade 3/4 HFS occurred in 9 patients (9.8%).

Conclusions

This study showed the efficacy and safely was comparable to other first line treatment regimens. The results support IRIS/cetuximab is more convenient and provide treatment flexibility in first line treatment with metastatic colorectal cancers.

Clinical trial identification

UMIN000015835.

Legal entity responsible for the study

This work was supported by CReS Kyushu with funding from Merck Serono, Japan, under a research contract.

Funding

Merck Serono.

Editorial Acknowledgement

Disclosure

E. Oki: Honoraria for lecturing: Bayer Yakuhin, Ltd, Japan; Eli Lilly Japan K.K.; Taiho Pharmaceutical Co., Ltd.; Yakult Honsha Co., Ltd.; Merck Serono Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Johnson & Johnson K.K.; and Chugai Pharmaceutical Co., Ltd. M. Kotaka: Honoraria lecturing: Chugai Pharmaceutical Co., Ltd. H. Baba, Y. Maehara: Lecture fees: Taiho Pharm; Grant research funding: Taiho Pharm, Merck Serono, Yakult Honsha, Japan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.